Health-related quality of life in diabetes: The associations of complications with EQ-5D scores

Oddvar Solli, Knut Stavem, I S Kristiansen, Oddvar Solli, Knut Stavem, I S Kristiansen

Abstract

Background: The aim of this study was to describe how diabetes complications influence the health-related quality of life of individuals with diabetes using the individual EQ-5D dimensions and the EQ-5D index.

Methods: We mailed a questionnaire to 1,000 individuals with diabetes type 1 and 2 in Norway. The questionnaire had questions about socio-demographic characteristics, use of health care, diabetes complications and finally the EQ-5D descriptive system. Logistic regressions were used to explore determinants of responses in the EQ-5D dimensions, and robust linear regression was used to explore determinants of the EQ-5D index.

Results: In multivariate analyses the strongest determinants of reduced MOBILITY were neuropathy and ischemic heart disease. In the ANXIETY/DEPRESSION dimension of the EQ-5D, "fear of hypoglycaemia" was a strong determinant. For those without complications, the EQ-5D index was 0.90 (type 1 diabetes) and 0.85 (type 2 diabetes). For those with complications, the EQ-5D index was 0.68 (type 1 diabetes) and 0.73 (type 2 diabetes). In the linear regression the factors with the greatest negative impact on the EQ-5D index were ischemic heart disease (type 1 diabetes), stroke (both diabetes types), neuropathy (both diabetes types), and fear of hypoglycaemia (type 2 diabetes).

Conclusions: The EQ-5D dimensions and the EQ-5D seem capable of capturing the consequences of diabetes-related complications, and such complications may have substantial impact on several dimensions of health-related quality of life (HRQoL). The strongest determinants of reduced HRQoL in people with diabetes were ischemic heart disease, stroke and neuropathy.

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047.
    1. Grandy S, Fox K. EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) Health and Quality of Life Outcomes. 2008;6:18. doi: 10.1186/1477-7525-6-18.
    1. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality of life in type 2 diabetes (TARDIS-2) Value Health. 2000;3(Suppl 1):47–51. doi: 10.1046/j.1524-4733.2000.36028.x.
    1. Koopmanschap M. Coping with Type II diabetes: the patient's perspective. Diabetologia. 2002;45:S18–S22.
    1. Wexler D, Grant R, Wittenberg E, Bosch J, Cagliero E, Delahanty L. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49:1489–1497. doi: 10.1007/s00125-006-0249-9.
    1. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res. 1999;8:79–91. doi: 10.1023/A:1026485130100.
    1. Fitzgerald JT, Davis WK, Connell CM, Hess GE, Funnell MM, Hiss RG. Development and validation of the Diabetes Care Profile. Eval Health Prof. 1996;19:208–230. doi: 10.1177/016327879601900205.
    1. Hirsch A, Bartholomae C, Volmer T. Dimensions of quality of life in people with non-insulin-dependent diabetes. Quality of Life Research. 2000;9:207–218. doi: 10.1023/A:1008959810698.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. Sintonen H. [Health-related quality of life measures] Sairaanhoitaja. 1993. pp. 17–19.
    1. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33:375–384. doi: 10.3109/07853890109002092.
    1. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health and Quality of Life Outcomes. 2003;1:54. doi: 10.1186/1477-7525-1-54.
    1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics. 2002;21:271–292. doi: 10.1016/S0167-6296(01)00130-8.
    1. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118–133.
    1. Klarman HEPh, Francis JO, Rosenthal GDP. Cost Effectiveness Analysis Applied to the Treatment of Chronic Renal Disease. [Article] Medical Care. 1968;6:48–54. doi: 10.1097/00005650-196801000-00005.
    1. Glasziou P, Alexander J, Beller E, Clarke P. the ADVANCE Collaborative Group. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health and Quality of Life Outcomes. 2007;5:21. doi: 10.1186/1477-7525-5-21.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108. doi: 10.1097/00005650-199711000-00002.
    1. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26:315–327. doi: 10.1111/j.1464-5491.2009.02682.x.
    1. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999;22:1125–1136. doi: 10.2337/diacare.22.7.1125.
    1. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16:1251–1265. doi: 10.1007/s11136-007-9226-0.
    1. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008;11:478–486. doi: 10.1111/j.1524-4733.2007.00260.x.
    1. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621–635. doi: 10.1023/A:1013171831202.
    1. Norinder AGPK. In: Proceedings of the 18th Plenary Meeting of the EuroQol Group. Roos P, editor. 2002. Estimating Danish EuroQol tariffs using the Time Trade off (TTO) and Visula Analogue Scale (VAS) Methods; pp. 257–292.
    1. Nord E. EuroQol®: health-related quality of life measurement. Valuations of health states by the general public in Norway. Health Policy. 1991;18:25–36. doi: 10.1016/0168-8510(91)90141-J.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa